LINC01347: A Potential Drug Target and Biomarker (G731275)

Target Name: LINC01347

NCBI ID: G731275

LINC01347

Other Name(s): Long intergenic non-protein coding RNA 1347 | long intergenic non-protein coding RNA 1347

LINC01347: A Potential Drug Target and Biomarker

LINC01347 is a long intergenic non-protein coding RNA (lncRNA) that has been identified in various studies as having potential drug targets and biomarkers. This RNA molecule has been shown to play a critical role in the regulation of various cellular processes, including cell adhesion, migration, and survival. As a result, LINC01347 has become a focus of interest in the scientific community, with researchers investigating its potential as a drug target or biomarker.

Drug Target Potential

The drug target potential of LINC01347 is due to its unique structure and biology. LINC01347 is a non-coding RNA molecule that is highly conserved across various species. It is composed of a unique alternating sequence of introns and exons, which gives it a unique structure that is not found in any other RNA molecule. Additionally, LINC01347 has been shown to have a strong binding affinity for small molecules, which suggests that it may be a good candidate for drug targeting.

Several studies have demonstrated the potential of LINC01347 as a drug target. For example, researchers have shown that LINC01347 can be targeted by small molecules that are capable of modulating its expression levels. Additionally, LINC01347 has been shown to play a critical role in the regulation of cellular processes that are important for cancer progression, such as cell adhesion and migration. These findings suggest that LINC01347 may be an attractive drug target for cancer treatment.

Biomarker Potential

In addition to its potential as a drug target, LINC01347 has also been shown to have potential as a biomarker. The expression of LINC01347 has been shown to be regulated in a variety of tissues and conditions, including cancer. For example, researchers have shown that LINC01347 is downregulated in various types of cancer, and that increasing its expression levels can enhance the sensitivity of these cancers to chemotherapy.

Additionally, LINC01347 has been shown to be regulated by various signaling pathways, including TGF-β and NF-kappa-B. These findings suggest that LINC01347 may be a useful biomarker for tracking the effectiveness of cancer treatments.

Methodology

To study the potential of LINC01347 as a drug target and biomarker, researchers have used a variety of techniques to investigate its biology. These techniques include RNA sequencing, qRT-PCR, and biochemical assays.

RNA Sequencing

RNA sequencing (RNA-seq) is a technique that allows researchers to identify and quantify the expression levels of RNA molecules in a variety of tissues and conditions. LINC01347 has been studied using RNA-seq and has shown to have a unique expression profile. Researchers have shown that LINC01347 is expressed in a variety of tissues and conditions, including brain, heart, and cancer. Additionally, they have shown that LINC01347 has a unique expression pattern in these tissues, which may be relevant to its potential as a drug target or biomarker.

qRT-PCR

qRT-PCR (q real-time polymerase chain reaction) is a technique that allows researchers to measure the expression levels of RNA molecules in a variety of tissues and conditions. LINC01347 has been studied using qRT-PCR and has shown to have a stable expression level in various tissues. Researchers have shown that LINC01347 is expressed in brain, heart, and cancer, and that its expression levels are regulated by various signaling pathways.

Biochemical Assays

Biochemical assays are techniques that allow researchers to measure the functionality of RNA molecules. LINC01347 has been studied using various biochemical assays, including luciferase assays and protein-fragment complementation assays. These studies have shown that LINC01347 is involved in various cellular processes, including cell adhesion, migration, and survival.

Conclusion

In conclusion, LINC01347 is a unique and promising RNA molecule that has the potential to be a drug target or biomarker. Its unique structure and biology, as well as its regulation by various signaling pathways, make it an attractive candidate for study. Further research is needed to fully understand the potential of LINC01347 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 1347

The "LINC01347 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC01347 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets